Page 1967 - Williams Hematology ( PDFDrive )

1942 Part XII: Hemostasis and Thrombosis Chapter 113: Molecular Biology and Biochemistry of the Coagulation Factors 1943

Role of Plasma Protease Inhibitors 11. Persson E, Olsen OH: Allosteric activation of coagulation factor VIIa. Front Biosci
(Landmark Ed) 16:3156–3163, 2011.
Circulating protease inhibitors are also critical for localizing the coagu- 12. Morawitz P: Die Chemie der Blutgerinnung. Ergeb Physiol 4:307–422, 1905.
lation reactions to specific cell surfaces by directly inhibiting proteases 13. Quick AJ: Hemorrhagic Diseases, pp 451–490. Lea and Febiger, Philadelphia, 1957.
that diffuse away from the site of clot formation. Not only are the plasma 14. Degen SJ: The prothrombin gene and its liver-specific expression. Semin Thromb
protease inhibitors key players in confining a clot to the proper location, Hemost 18:230–242, 1992.
their synergistic action imposes a threshold effect on the coagulation 15. Wu W, Suttie JW: N-glycosylation contributes to the intracellular stability of proth-
rombin precursors in the endoplasmic reticulum. Thromb Res 96:91–98, 1999.
process. 363,395,396 Thus, in the presence of inhibitors, coagulation does not 16. Bradford HN, Orcutt SJ, Krishnaswamy S: Membrane binding by prothrombin
proceed unless procoagulant factors are generated in sufficient amounts mediates its constrained presentation to prothrombinase for cleavage. J Biol Chem
288:27789–27800, 2013.
to overcome the inhibitory mechanisms. In case the triggering event 17. Krishnaswamy S: The transition of prothrombin to thrombin. J Thromb Haemost 11
is inadequate, the system returns to baseline rather than continuing (Suppl 1):265–276, 2013.
through the coagulation process. Under pathologic conditions, the trig- 18. Bradford HN, Krishnaswamy S: Meizothrombin is an unexpectedly zymogen-like vari-
ger for clotting may be so strong as to overwhelm the control mecha- ant of thrombin. J Biol Chem 287:30414–30425, 2012.
nisms, leading to disseminated intravascular coagulation or thrombosis 19. Bode W, Turk D, Karshikov A: The refined 1.9-A X-ray crystal structure of D-Phe-Pro-
Arg chloromethylketone-inhibited human alpha-thrombin: Structure analysis, overall
(Chaps. 129 and 133). structure, electrostatic properties, detailed active-site geometry, and structure-function
relationships. Protein Sci 1:426–471, 1992.
20. Lechtenberg BC, Freund SM, Huntington JA: An ensemble view of thrombin allostery.
ROLE OF FIBRINOLYSIS Biol Chem 393:889–898, 2012.
21. Lechtenberg BC, Johnson DJ, Freund SM, Huntington JA: NMR resonance assignments
Once a hemostatic clot has been formed and protected from fibrinolysis of thrombin reveal the conformational and dynamic effects of ligation. Proc Natl Acad
by the action of factor XIII and TAFI, some provision must be made Sci U S A 107:14087–14092, 2010.
for its eventual removal as wound healing takes place. Dissolution of 22. Vu TK, Hung DT, Wheaton VI, Coughlin SR: Molecular cloning of a functional
clots is accomplished by the fibrinolytic system, as discussed in detail thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell
64:1057–1068, 1991.
in Chap. 135. 23. Ishihara H, Connolly AJ, Zeng D, et al: Protease-activated receptor 3 is a second
thrombin receptor in humans. Nature 386:502–506, 1997.
The Concept of Basal Coagulation and Anticoagulation 24. Xu WF, Andersen H, Whitmore TE, et al: Cloning and characterization of human pro-
tease-activated receptor 4. Proc Natl Acad Sci U S A 95:6642–6646, 1998.
The coagulation process only proceeds when enough thrombin is gen- 25. Coughlin SR: Protease-activated receptors in hemostasis, thrombosis and vascular biol-
erated on or near the tissue factor–bearing cell to trigger activation of ogy. J Thromb Haemost 2005:1800–1814.
platelets and cofactors. One may wonder, however, if minute hemostatic 26. Spronk HM, de Jong AM, Crijns HJ, et al: Pleiotropic effects of factor Xa and thrombin:
What to expect from novel anticoagulants. Cardiovasc Res 101:344–351, 2014.
plugs are not constantly formed throughout the body to maintain the 27. Coppens M, Eikelboom JW, Gustafsson D, et al: Translational success stories: Develop-
integrity of the vasculature. Indeed, a low level of coagulation factor ment of direct thrombin inhibitors. Circ Res 111:920–929, 2012.
activation probably occurs at all times. More than 30 years ago, it 28. Hauel NH, Nar H, Priepke H, et al: Structure-based design of novel potent nonpeptide
397
thrombin inhibitors. J Med Chem 45:1757–1766, 2002.
was shown that fibrinopeptides are continuously cleaved from fibrin- 29. Royle NJ, Irwin DM, Koschinsky ML, et al: Human genes encoding prothrombin and
ogen at low levels in normal individuals. Minute amounts of factor ceruloplasmin map to 11p11-q12 and 3q21–24, respectively. Somat Cell Mol Genet
398
VIIa as well as the activation peptides of factors IX and X have also 13:285–292, 1987.
been demonstrated to circulate in the bloodstream of normal individ- 30. Peyvandi F, Bolton-Maggs PH, Batorova A, De Moerloose P: Rare bleeding disorders.
Haemophilia 18 (Suppl 4):148–153, 2012.
uals. 399–401 This is known as basal coagulation or idling. Basal activation 31. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in
of coagulation factors likely results from minor injuries that occur dur- the 3′-untranslated region of the prothrombin gene is associated with elevated plasma
ing normal daily activities. The basal coagulation must be balanced by prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703, 1996.
basal activity of the anticoagulation and fibrinolytic systems. This is evi- 32. Gehring NH, Frede U, Neu-Yilik G, et al: Increased efficiency of mRNA 3′ end forma-
tion: A new genetic mechanism contributing to hereditary thrombophilia. Nat Genet
denced by the presence of low levels of the protein C activation peptide 28:389–392, 2001.
and tissue plasminogen activator activity in normal individuals. 402 33. Rosendaal FR, Doggen CJ, Zivelin A, et al: Geographic distribution of the 20210 G to A
prothrombin variant. Thromb Haemost 79:706–708, 1998.
34. Giangrande PLF: Six characters in search of an author: The history of the nomenclature
of coagulation factors. Br J Haematol 121:703–712, 2003.
REFERENCES 35. Hansson K, Stenflo J: Post-translational modifications in proteins involved in blood
coagulation. J Thromb Haemost 3:2633–2648, 2005.
1. Davidson CJ, Hirt RP, Lal K, et al: Molecular evolution of the vertebrate blood coagula- 36. Butenas S, Mann KG: Kinetics of human factor VII activation. Biochemistry
tion network. Thromb Haemost 89:420–428, 2003. 35:1904–1910, 1996.
2. Patthy L: Evolution of the proteases of blood coagulation and fibrinolysis by assembly 37. Neuenschwander PF, Fiore MM, Morrissey JH: Factor VII autoactivation proceeds via
from modules. Cell 41:657–663, 1985. interaction of distinct protease-cofactor and zymogen-cofactor complexes. Implica-
3. Wu SM, Cheung WF, Frazier D, Stafford DW: Cloning and expression of the cDNA for tions of a two-dimensional enzyme kinetic mechanism. J Biol Chem 268:21489–21492,
human gamma-glutamyl carboxylase. Science 254:1634–1636, 1991. 1993.
4. Li T, Chang C-Y, Jin D-Y, et al: Identification of the gene for vitamin K epoxide reduc- 38. Camerer E, Huang W, Coughlin SR: Tissue factor- and factor X-dependent activation
tase. Nature 427:541–544, 2004. of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A 97:5255–5260,
5. Jorgensen MJ, Cantor AB, Furie BC, et al: Recognition site directing vitamin K- 2000.
dependent gamma-carboxylation resides on the propeptide of factor IX. Cell 48:185– 39. Hoffman M, Monroe DM: The multiple roles of tissue factor in wound healing. Front
191, 1987. Biosci (Schol Ed) 4:713–721, 2012.
6. Huber P, Schmitz T, Griffin J, et al: Identification of amino acids in the gamma-car- 40. Riewald M, Ruf W: Mechanistic coupling of protease signaling and initiation of coagu-
boxylation recognition site on the propeptide of prothrombin. J Biol Chem 265:12467– lation by tissue factor. Proc Natl Acad Sci U S A 98:7742–7747, 2001.
12473, 1990. 41. O’Hara PJ, Grant FJ: The human factor VII gene is polymorphic due to variation in
7. Falls LA, Furie BC, Jacobs M, et al: The omega-loop region of the human prothrombin repeat copy number in a minisatellite. Gene 66:147–158, 1988.
gamma-carboxyglutamic acid domain penetrates anionic phospholipid membranes. J 42. Berkner K, Busby S, Davie E, et al: Isolation and expression of cDNAs encoding human
Biol Chem 276:23895–23902, 2001. factor VII. Cold Spring Harb Symp Quant Biol 51(Pt 1):531–541, 1986.
8. Huang M, Rigby AC, Morelli X, et al: Structural basis of membrane binding by Gla 43. Girelli D, Russo C, Ferraresi P, et al: Polymorphisms in the factor VII gene and the
domains of vitamin K-dependent proteins. Nat Struct Biol 10:751–756, 2003. risk of myocardial infarction in patients with coronary artery disease. N Engl J Med
9. Tavoosi N, Davis-Harrison RL, Pogorelov TV, et al: Molecular determinants of phos- 343:774–780, 2000.
pholipid synergy in blood clotting. J Biol Chem 286:23247–23253, 2011. 44. Biggs R, Douglas AS, MacFarlane RG, et al: Christmas disease: A condition previously
10. Bode W, Mayr I, Baumann U, et al: The refined 1.9 A crystal structure of human alpha- mistaken for haemophilia. Br Med J 2:1378–1382, 1952.
thrombin: Interaction with D-Phe-Pro-Arg chloromethylketone and significance of the 45. Gillis S, Furie BC, Furie B, et al: gamma-Carboxyglutamic acids 36 and 40 do not con-
Tyr-Pro-Pro-Trp insertion segment. EMBO J 8:3467–3475, 1989. tribute to human factor IX function. Protein Sci 6:185–196, 1997.

Kaushansky_chapter 113_p1915-1948.indd 1942 9/21/15 2:41 PM